JF
HRTX icon

JMN Financial’s Heron Therapeutics HRTX Stock Holding History

JMN Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.81K Buy
+11,269
New +$9.04K ﹤0.01% 228

Other funds holding HRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JMN Financial's HRTX Position: Q2 2026 in Review

JMN Financial opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 11,269 shares worth $4.81K. The stake represents ﹤0.01% of the portfolio and ranks #228 among its holdings.

153 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • JMN Financial held 11,269 shares of Heron Therapeutics worth $4.81K as of Q2 2026.
  • Heron Therapeutics was a new JMN Financial position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of JMN Financial's portfolio in Q2 2026, its #228 holding.
  • 153 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on JMN Financial's 13F filing for Q2 2026, filed 10 Aug 2026.